Aurora Cannabis Advances Powdery Mildew-Resistant Cannabis Into Production Trials
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurora Cannabis ( (TSE:ACB) ) has issued an update.
On January 14, 2026, Aurora Cannabis announced that it has made significant progress in its research into powdery mildew resistance, nearly a year after discovering a novel genetic resistance source known as PM2. The company has conducted multiple breeding cycles and controlled infection trials to transfer this PM2 resistance into elite cannabis lines, aiming to preserve high-quality traits while boosting disease resistance, and has advanced to production trials at its Aurora Ridge facility. Aurora has presented this work at several scientific and industry conferences, underscoring its ambition to lead in cannabis science, and notes that the underlying genetic marker technology, developed at its Aurora Coast R&D hub in collaboration with academic and funding partners, is patent pending in multiple major markets. Successful production trials are expected to strengthen Aurora’s operational efficiency and product quality by protecting plant health and reducing costs, reinforcing its competitive position and intellectual property portfolio in the global medical cannabis industry.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$6.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Spark’s Take on TSE:ACB Stock
According to Spark, TipRanks’ AI Analyst, TSE:ACB is a Neutral.
Aurora Cannabis faces significant financial challenges, with ongoing losses and cash flow issues weighing heavily on its score. While recent earnings call highlights and strategic investments in international markets provide some optimism, the overall outlook remains cautious due to valuation concerns and technical indicators suggesting bearish momentum.
To see Spark’s full report on TSE:ACB stock, click here.
More about Aurora Cannabis
Aurora Cannabis Inc. is a Canadian-based, science-driven global medical and consumer cannabis company serving markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, it operates a portfolio of adult-use and medical cannabis brands, and also holds a controlling interest in Bevo Farms, a major North American supplier of propagated agricultural plants, positioning Aurora as a significant player in both cannabis and broader horticultural supply chains.
Average Trading Volume: 577,247
Technical Sentiment Signal: Sell
Current Market Cap: C$335.7M
See more data about ACB stock on TipRanks’ Stock Analysis page.
